BIIB112

BIOLOGICAL2 trials

Sponsors

Biogen, NightstaRx Ltd, a Biogen Company

Conditions

ChoroideremiaX-Linked Retinitis Pigmentosa

Phase 1

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112

CompletedNCT03116113

BiogenX-Linked Retinitis Pigmentosa

Start: 2017-03-08End: 2020-11-18Updated: 2024-01-18

Phase 3

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

CompletedNCT03584165

NightstaRx Ltd, a Biogen CompanyChoroideremia, X-Linked Retinitis Pigmentosa

Start: 2018-06-04End: 2026-06-22Updated: 2026-07-06

Related Papers

Microperimetry as an Outcome Measure Improves Patient Eligibility and Efficacy Detection in RPGR Gene Therapy Trials.

2026-06-12

Systematic Identification of Candidate Genes for Inherited Retinal Disease Gene Therapy Integrating Worldwide IRD Cohort and Single-Cell Analysis.

2025-06-12

Early‐Onset Cone Photoreceptor Degeneration Is Associated With High Myopia in <i>RPGR</i>‐Related Retinal Dystrophy

Journal of Ophthalmology2025-01-01

Gene therapy for choroideremia using an adeno-associated viral vector encoding Rab escort protein 1: the REGENERATE open-label trial

Efficacy and Mechanism Evaluation2024-05-019 citations

Assessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study.

2024-02-2823 citations

Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With <i>RPGR</i> Gene Variations

JAMA Ophthalmology2023-02-0956 citations

Viral Vector Technologies and Strategies: Improving on Nature

International Ophthalmology Clinics2021-07-015 citations

Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR.

2020-02-24282 citations